AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03890003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Study NCT01640405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: modified FOLFOX6 + bevacizumab
Description: * Bevacizumab 5 mg/kg iv, day 1, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~* 5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~  * LV 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
Study NCT01640405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Bevacizumab
Description: * Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~* LV 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
Study NCT04252274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir and Cobicistat
Description: Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
Study NCT04419129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford UKA
Description: knee arthroplasty
Study NCT04419129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard TKA
Description: knee arthroplasty
Study NCT01293253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stair walking
Description: Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
Study NCT01293253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair walking
Description: Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
Study NCT04605289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lemongrass essential oil gel
Description: The lemongrass oil gel will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week.
Study NCT04605289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week.
Study NCT04605289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Conventional mechanical treatment by ultra-sonic scalers
Study NCT04605289 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Conventional mechanical treatment by ultra-sonic scalers
Study NCT04996446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
Study NCT04996446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALPPS surgery
Description: In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 4-8 weeks after stage I surgery; In control group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
Study NCT04996446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALPPS surgery
Description: In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 4-8 weeks after stage I surgery; In control group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
Study NCT01853202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training
Study NCT00133809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation of Human Islets
Description: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
Study NCT03005353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cumin seed extract
Description: patients will receive the drug in suppository form
Study NCT03005353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clotrimazole
Description: patients will receive the drug in suppository form
Study NCT03589807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.
Study NCT02517814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT01340248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend 64mg capsule
Description: 1. Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~2. Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting
Study NCT04376151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commiment Therapy (ACT) bibliotherapy 'Get Out of Your Mind and Into Your Life'
Description: The intervention has been described in the arm/group descriptions.
Study NCT01920477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product
Study NCT01920477 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
Study NCT01002677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advocacy training curriculum
Description: Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
Study NCT01002677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed
Description: Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
Study NCT00132899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate and infliximab combination
Study NCT00132899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and infliximab combination therapy.
Study NCT02801695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: Citrulline supplementation
Study NCT02801695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01828905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CERAMENT™|BONE VOID FILLER
Description: ceramic bone void filler
Study NCT01828905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous cancellous bone graft
Description: autologous cancellous bone graft
Study NCT03956251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Mineralized/Demineralized Putty Allograft
Description: At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft
Study NCT03956251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Putty Allograft
Description: At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
Study NCT00453167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
Study NCT00453167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
Study NCT04056988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere
Description: Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
Study NCT00211068 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
Study NCT02537210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: Patients will be prescribed Asacol 2g daily for 12 months
Study NCT02537210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will be prescribed placebo 5 capsules daily for 12 months
Study NCT00004853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC >=10,000/microliter
Study NCT00004853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-SD/01
Description: 100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
Study NCT01718808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
Study NCT01718808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
Study NCT01666587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant
Study NCT01666587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin inhibitor (Ibuprophen)
Study NCT03621462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Dermatology Assistant (AIDA™)
Description: The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
Study NCT04245553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal Point of Care Ultrasound
Description: Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.
Study NCT00918879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Oral tablet, once daily for 24 weeks
Study NCT00918879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, once daily for 24 weeks
Study NCT01431820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Solution, 10%
Description: Topical
Study NCT01431820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Topical
Study NCT03981848 — intervention group
Intervention type: OTHER
Intervention: Risk model of tumor relapse
Description: High risk factor model of tumor relapse after liver transplantation
Study NCT00402012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
Study NCT03211234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0 mg DE-122 Injectable Solution + Lucentis
Description: Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
Study NCT03211234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0 mg DE-122 Injectable Solution + Lucentis
Description: Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
Study NCT03211234 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lucentis
Description: Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
Study NCT03814577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Total Antioxidant Status
Description: Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
Study NCT03814577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Total Antioxidant Status
Description: Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
Study NCT03814577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Total Oxidant Status
Description: Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
Study NCT03814577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Total Oxidant Status
Description: Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
Study NCT03814577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index
Description: Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.
Study NCT03814577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index
Description: Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.
Study NCT03814577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invasive arterial monitorization
Description: Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
Study NCT03814577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invasive arterial monitorization
Description: Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
Study NCT02277054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen-MPC cornea
Description: Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
Study NCT00699153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate
Description: Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
Study NCT00699153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Ophthalmic Loteprednol Etabonate
Description: Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
Study NCT02468362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic intersphincteric resection
Description: laparoscopic intersphincteric resection for low rectal cancer
Study NCT02468362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open intersphincteric resection
Study NCT03004001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 150 mg biweekly
Study NCT03004001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab placebo
Description: placebo
Study NCT03004001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg/day
Study NCT03004001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg/day
Study NCT00527358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)
Description: 1. community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~2. youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~3. school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~4. Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training.
Study NCT03589807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Description: Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
Study NCT02936726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, Health Coaching and Meditation
Description: Comparing Exercise, Health Coaching and Meditation In Combination
Study NCT02936726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Health Coaching
Description: Comparing Exercise and Health Coaching Alone
Study NCT03589807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.